Lung Cancer
Volume 45 , Pages S93-S96 , August 2004

Considerations for post-operative radiotherapy to the hemithorax following extrapleural pneumonectomy in malignant pleural mesothelioma

  • Suresh Senan

      Affiliations

    • Department of Radiation Oncology, Vu University Medical Center, De Boelelaan 1117, PO box 7057, 1007 MB Amsterdam, The Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +31-20-444-0414; fax: +31-20-444-0410.
    • ,
  • Marjan van de Pol

      Affiliations

    • Department of Radiation Oncology, Erasmus MC—Daniel den Hoed Cancer Center, Rotterdam, The Netherlands

References 

  1. Rusch VW, Piantadosi S, Holmes EC. The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial. J. Thorac. Cardiovasc. Surg. 1991;102:1–9
  2. Pass HI, Kranda K, Temeck BK, Feuerstein I, Steinberg SM. Surgically debulked malignant pleural mesothelioma: results and prognostic factors. Ann. Surg. Oncol. 1997;4:215–222
  3. Baldini EH, Recht A, Strauss GM, DeCamp MM, Swanson SJ, Liptay MJ, et al.  Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Ann. Thorac. Surg. 1997;63:334–338
  4. Rusch VW, Rosenzweig K, Venkatraman E, Leon L, Raben A, Harrison L, et al.  A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg. 2001;122:788–795
  5. Yajnik S, Rosenzweig KE, Mychalczak B, Krug L, Flores R, Hong L, et al.  Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma. Int. J. Radiat. Oncol. Biol. Phys. 2003;56:1319–1326
  6. Ahamad A, Stevens CW, Smythe WR, Vaporciyan AA, Komaki R, Kelly JF, et al.  Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma. Int. J. Radiat. Oncol. Biol. Phys. 2003;55:768–775
  7. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al.  Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 2003;21:2636–2644
  8. Green MR. Alimta (pemetrexed disodium): a multitargeted antifolate for the treatment of mesothelioma. Lung Cancer. 2002;38:s55–s57
  9. Graham MV, Purdy JA, Emami B, Harms W, Bosch W, Lockett MA, et al.  Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int. J. Radiat. Oncol. Biol. Phys. 1999;45:323–329
  10. Dawson LA, Normolle D, Balter JM, McGinn CJ, Lawrence TS, Ten Haken RK. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int. J. Radiat. Oncol. Biol. Phys. 2002;53:810–821
  11. Burman C, Kutcher GJ, Emami B, Goitein M. Fitting of normal tissue tolerance data to an analytic function. Int. J. Radiat. Oncol. Biol. Phys. 1991;21:123–135
  12. Intensity Modulated Radiation Therapy Collaborative Working Group. Intensity-modulated radiotherapy: current status and issues of interest. Int J Radiat Oncol Biol Phys 2001;51:880–914.
  13. Forster KM, Smythe WR, Starkschall G, Liao Z, Takanaka T, Kelly JF, et al.  Intensity-modulated radiotherapy following extrapleural pneumonectomy for the treatment of malignant mesothelioma: clinical implementation. Int. J. Radiat. Oncol. Biol. Phys. 2003;55:606–616

PII: S0169-5002(04)00180-1

doi: 10.1016/j.lungcan.2004.04.019

Lung Cancer
Volume 45 , Pages S93-S96 , August 2004

Article Tools